Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Cost of Revenue (2020 - 2025)

Historic Cost of Revenue for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $11.0 million.

  • Xeris Biopharma Holdings' Cost of Revenue fell 1910.54% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.1 million, marking a year-over-year increase of 1768.41%. This contributed to the annual value of $36.8 million for FY2024, which is 2858.09% up from last year.
  • Xeris Biopharma Holdings' Cost of Revenue amounted to $11.0 million in Q3 2025, which was down 1910.54% from $11.9 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Cost of Revenue registered a high of $13.6 million during Q3 2024, and its lowest value of $1.8 million during Q1 2021.
  • Over the past 5 years, Xeris Biopharma Holdings' median Cost of Revenue value was $6.3 million (recorded in 2022), while the average stood at $7.0 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first surged by 24353.78% in 2022, then crashed by 1910.54% in 2025.
  • Xeris Biopharma Holdings' Cost of Revenue (Quarter) stood at $4.9 million in 2021, then rose by 28.68% to $6.3 million in 2022, then increased by 20.33% to $7.6 million in 2023, then grew by 25.2% to $9.5 million in 2024, then grew by 16.02% to $11.0 million in 2025.
  • Its Cost of Revenue was $11.0 million in Q3 2025, compared to $11.9 million in Q2 2025 and $8.7 million in Q1 2025.